Expanded Access Program (EAP) to Provide Nusinersen to Patients With Infantile-onset Spinal Muscular Atrophy (SMA)
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Expanded access; Therapeutic Use
- Sponsors Biogen
- 07 Nov 2016 Status changed from planning to recruiting, according to a Biogen and Ionis Pharmaceuticals media release.
- 07 Nov 2016 According to a Biogen and Ionis Pharmaceuticals media release, the company will continue to explore where and when the EAP may be broadened to include patients with later-onset SMA (consistent with Type 2).
- 10 Aug 2016 New trial record